Chimeric antigen receptor (CAR) T cells hold great promise for targeting and fighting cancer. However, their efficacy in solid tumors has been below expectations, as the tumor microenvironment (TME) limits their infiltration and produces a range of immune-inhibitory molecules to deactivate T cells. Researchers are developing new strategies to enhance CAR-T cell therapy for solid tumors by disrupting the TME and promoting T cell persistence. In this webinar, Katie McKenna, PhD, will discuss how she uses CAR-T cells in combination with mesenchymal stromal cells that deliver engineered adenoviruses to stimulate the immune response in the TME.
- Targeting non-small cell lung cancer using a cell carrier system to deliver an oncolytic and immunostimulatory adenovirus
- Efficacy of oncolytic virotherapy in 3D cell culture and in vivo
- Assessing T cell functionality with single-cell proteomics
Watch the on-demand webinar below: